TABLE 1.
Member Characteristics and Results
| Member Count (% Female) | Median Age, Years | Total Claims (% Female) | Percentage Adherent (MPR ≥ 0.8)a | Top Switched-to Drugb | ADA Switch Rate | ETN Switch Rate | Retail Pharmacy Adherence | Specialty Pharmacy Adherence | |
|---|---|---|---|---|---|---|---|---|---|
| RA overall | 456 (77.9) | 50 | 6,943 (78) | 77% | ABA (n = 39) | 35% (n = 79) | 34% (n = 85) | 70% (n = 166)c | 79% (n = 414)c |
| Drug Name | |||||||||
| ABT | ADA | CTZ | ETN | GOL | IFX | RTX | TOF | TCZ | |
| Patient count | 47 | 226 | 27 | 252 | 27 | 38 | 34 | 19 | 28 |
| Claim count | 358 | 2,434 | 330 | 2,639 | 222 | 308 | 170 | 153 | 301 |
| Adherence (%)d | 70 | 77 | 75 | 76 | 95 | – | – | 83 | 71 |
a Members using more than 1 target drug had more than 1 data point for adherence, 1 per target prescription drug.
b Reflects top switched-to drug, excluding ADA or ETN.
c Some RA patients filled their drugs at unspecified locations excluding them from the retail or specialty analysis.
d Adherence was only calculated for prescription drugs.
ABT = abatacept; ADA = adalimumab; bDMARD = biologic disease-modifying antirheumatic drug; CTZ = certolizumab; ETN = etanercept; GOL = golimumab; IFX = infliximab; MPR = medication possession ratio; RA = rheumatoid arthritis; RTX = rituximab; TCZ = tocilizumab; TOF = tofacitinib.